- Home
- CTW vs PRQR Comparison
CTW vs PRQR Comparison
Compare CTW & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTW | PRQR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Japan | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 244.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTW | PRQR |
|---|---|---|
| Price | $2.29 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 19.1K | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.33 |
| 52 Week High | $3.14 | $3.10 |
Technical Indicators
Market Signals| Indicator | CTW | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 50.08 |
| Support Level | $1.98 | $1.37 |
| Resistance Level | $2.51 | $1.76 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 33.33 | 43.30 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.